Galmed Pharmaceuticals earnings were -$11.1M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest GLMD earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$1.9M, down 60.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, GLMD reported annual earnings of -$10.3M, with 37.1% growth. The next GLMD earnings date is Aug 27, 2026.
Galmed Pharmaceuticals Earnings Reports & History FAQ
What were Galmed Pharmaceuticals's earnings last quarter?
On GLMD's earnings call on Jun 25, 2026, Galmed Pharmaceuticals (NASDAQ: GLMD) reported Q1 2026 earnings per share (EPS) of -$0.29, up 53.23% year over year. Total GLMD earnings for the quarter were -$1.91 million. In the same quarter last year, Galmed Pharmaceuticals's earnings per share (EPS) was -$0.62.
The next GLMD earnings call is Aug 27, 2026. Add GLMD to your watchlist to be reminded of Galmed Pharmaceuticals's next earnings date.
Is Galmed Pharmaceuticals profitable or losing money?
As of the last Galmed Pharmaceuticals earnings report, Galmed Pharmaceuticals is currently losing money. Galmed Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$11.12 million, a 51.31% increase year over year.
What was GLMD's earnings growth in the past year?
As of Galmed Pharmaceuticals's earnings date in Jun 25, 2026, Galmed Pharmaceuticals's earnings has grown year over year. GLMD earnings in the past year totalled -$11.12 million.
What are Galmed Pharmaceuticals's earnings expectations?
The current EPS estimate for Galmed Pharmaceuticals's earnings report in Aug 27, 2026 is -$0.38.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.